EUVIMEDEUVIMED entdecken
Kohortenstudie

The Impact of Elexacaftor‐Tezacaftor‐Ivacaftor on Biochemical Surrogates of Cystic Fibrosis Hepatobiliary Involvement: A Retrospective Cohort Study

Sasha-Jane Abi-Aad iD, Athanasios Tsalatsanis iD, Michael Narkewicz iD, Daniel H Leung, Racha T Khalaf iD

Pediatric Pulmonology · 2026

DOI: 10.1002/ppul.71522 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Pediatric Pulmonology, 2026. Verfasst von Sasha-Jane Abi-Aad und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Pediatric Gastroenterology, Hepatology and Nutrition, University of South Florida Morsani College of Medicine, …. Hauptthemen laut MEDLINE: Cystic Fibrosis, Benzodioxoles, Indoles, Quinolones. Die Arbeit nennt 34 Literaturangaben. Gefördert von: Cystic Fibrosis Foundation, Gilead, Gilead Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Elexacaftor‐tezacaftor‐ivacaftor (ETI) has significantly improved lung function and growth in people with cystic fibrosis (pwCF). However, its impact on cystic fibrosis hepatobiliary involvement (CFHBI) remains unclear. This study aims to investigate the impact of ETI on biochemical surrogates of CFHBI using a large population database.

Methods

This 1:1 retrospective cohort study utilized TriNetX, a de‐identified multicenter database, and included people aged 6–21 years with ICD‐10 diagnostic codes for cystic fibrosis who were prescribed pancreatic enzyme replacement therapy. ETI group (pwCF on ETI seen from 1/1/2020 to 1/1/2024) and non‐ETI group (pwCF not on ETI seen from 1/1/2014 to 1/1/2018) were analyzed. Groups were matched using propensity scores, and statistical analyses were performed on TriNetX (significance set at p = 0.05).

Results

There were 533 children with CF (CwCF) aged 6–12 years and 1177 adolescents and young adults with CF aged 13–21 years in each cohort. In CwCF, the ETI group had significantly lower ALT (33 ± 44 U/L vs. 45 ± 57 U/L, p = 0.003) and GGT levels (18 ± 20 U/L vs. 28 ± 51 U/L, p = 0.004), as well as improved albumin and PT/INR compared to non‐ETI group. In pwCF (13–21), the ETI group had significantly lower GGT (21 ± 26 U/L vs. 32 ± 63 U/L, p = 0.002), and improved albumin and PT compared to non‐ETI group; however, indirect bilirubin was higher (0.7 ± 0.5 mg/dL vs. 0.3 ± 0.4 mg/dL, p < 0.001).

Conclusion

Our findings suggest that earlier ETI use in children with CF is associated with improved liver enzymes, offering reassurance against widespread drug‐induced liver injury. Long‐term follow‐up including imaging and biopsy when available, pre‐ and post‐ETI, is needed to better assess the impact of ETI on CFHBI and advanced CF liver disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisBenzodioxolesIndolesQuinolonesAminophenolsPyrrolidinesLiver DiseasesPyrazolesHumansRetrospective StudiesFemaleMaleAdolescentChildDrug CombinationsYoung AdultBiomarkersBilirubinPyridinesQuinolines

Stichwörter der Autor:innen

advanced cystic fibrosis liver disease (aCFLD)cystic fibrosis transmembrane conductance regulator (CFTR)liver enzymesmodulator therapy

Substanzen

BenzodioxolesIndolesDrug CombinationsQuinolonesBiomarkersAminophenolselexacaftor, ivacaftor, tezacaftor drug combinationBilirubinPyrrolidinestezacaftor, ivacaftor drug combination

Autor:innen und Institutionen

  • Department of Pediatrics, Division of Pediatric Gastroenterology, Hepatology and Nutrition, University of South Florida Morsani College of Medicine, Tampa, Florida, USA.
  • Research Methodology and Biostatistics Core, University of South Florida Morsani College of Medicine, Tampa, Florida, USA.
  • Department of Pediatrics, Digestive Health Institute, Children's Hospital Colorado, School of Medicine University of Colorado, Aurora, Colorado, USA.
  • Department of Pediatrics, Division of Pediatric Gastroenterology, Hepatology and Nutrition, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, USA.

ORCID-Profile: Sasha-Jane Abi-Aad, Athanasios Tsalatsanis, Michael Narkewicz, Racha T Khalaf

Förderung

  • Cystic Fibrosis Foundation
  • Gilead
  • Gilead Sciences

Zitieren

APA

Abi-Aad, S. J., Tsalatsanis, A., Narkewicz, M., Leung, D. H., & Khalaf, R. T. (2026). The Impact of Elexacaftor‐Tezacaftor‐Ivacaftor on Biochemical Surrogates of Cystic Fibrosis Hepatobiliary Involvement: A Retrospective Cohort Study. Pediatric Pulmonology. https://doi.org/10.1002/ppul.71522

Vancouver

Abi-Aad SJ, Tsalatsanis A, Narkewicz M, Leung DH, Khalaf RT. The Impact of Elexacaftor‐Tezacaftor‐Ivacaftor on Biochemical Surrogates of Cystic Fibrosis Hepatobiliary Involvement: A Retrospective Cohort Study. Pediatric Pulmonology. 2026. doi:10.1002/ppul.71522

BibTeX
@article{AbiAad2026,
  author = {Abi-Aad, Sasha-Jane and Tsalatsanis, Athanasios and Narkewicz, Michael and Leung, Daniel H and Khalaf, Racha T},
  title = {The Impact of Elexacaftor‐Tezacaftor‐Ivacaftor on Biochemical Surrogates of Cystic Fibrosis Hepatobiliary Involvement: A Retrospective Cohort Study},
  journal = {Pediatric Pulmonology},
  year = {2026},
  doi = {10.1002/ppul.71522}
}
Kostenlos starten →